CAMBRIDGE, Mass. (AP) _ Editas Medicine Inc. (EDIT) on Thursday reported third-quarter net income of $7.8 million, after reporting a loss in the same period a year earlier.

On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 12 cents.

The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 66 cents per share.

The genome editing company posted revenue of $62.8 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $7.3 million.

Editas shares have increased nearly 7% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $31.55, a rise of 49% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EDIT at https://www.zacks.com/ap/EDIT

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News